Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $17.00.

A number of equities analysts have issued reports on ZURA shares. Wall Street Zen upgraded shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Guggenheim increased their price target on shares of Zura Bio from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. William Blair initiated coverage on shares of Zura Bio in a research note on Wednesday, July 8th. They set an “outperform” rating for the company. Wedbush lifted their price objective on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Monday, July 6th.

Zura Bio Price Performance

Shares of NASDAQ:ZURA opened at $5.38 on Friday. The firm has a market capitalization of $515.57 million, a price-to-earnings ratio of -4.76 and a beta of -0.02. The business’s 50 day simple moving average is $5.61 and its 200-day simple moving average is $5.36. Zura Bio has a 12 month low of $1.88 and a 12 month high of $7.44.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. On average, equities analysts anticipate that Zura Bio will post -0.81 earnings per share for the current year.

Institutional Trading of Zura Bio

Several institutional investors and hedge funds have recently made changes to their positions in ZURA. California State Teachers Retirement System acquired a new position in shares of Zura Bio in the second quarter valued at approximately $28,000. Allworth Financial LP purchased a new position in shares of Zura Bio during the fourth quarter valued at approximately $30,000. Squarepoint Ops LLC boosted its position in Zura Bio by 34.6% during the fourth quarter. Squarepoint Ops LLC now owns 33,801 shares of the company’s stock worth $177,000 after acquiring an additional 8,680 shares during the last quarter. Bank of America Corp DE boosted its position in Zura Bio by 31.9% during the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after acquiring an additional 9,966 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in Zura Bio by 3.4% in the 1st quarter. Renaissance Technologies LLC now owns 313,300 shares of the company’s stock worth $1,864,000 after acquiring an additional 10,200 shares during the period. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.